Effect of benazepril and pimobendan on serum angiotensin‐converting enzyme activity in dogs. Issue 3 (2nd February 2018)

• Record Type: Journal Article
• Authors: King, J. N.; Christinaz, C.; Strehlau, G.; Hornfeld, J.
• Is Part Of: Journal of veterinary pharmacology and therapeutics. Volume 41:Issue 3(2018)
• Page Start: 485
• Page End: 489
• Publication Date: 2018-02-02
• Subjects: ACE inhibitor -- angiotensin‐converting enzyme -- benazepril -- dog -- pimobendan; Veterinary pharmacology -- Periodicals; Therapeutics -- Periodicals; 636.0895105
• DOI: 10.1111/jvp.12475
• Languages: English
• ISSNs: 0140-7783

Abstract

Abstract : To support their combined use, the objective of the study was to evaluate the effects of benazepril and pimobendan on serum angiotensin‐converting enzyme (ACE) activity in dogs. A total of 48 healthy beagle dogs were randomized into four groups ( n = 12 per group) in a parallel‐group design study: A (control, placebo twice daily (BID)); B (0.5–1.0 mg/kg benazepril once daily (SID) in the morning, placebo in the evening); C (0.25–0.5 mg/kg benazepril BID); D (0.25–0.5 mg/kg benazepril and 0.125–0.25 mg/kg pimobendan, both BID). The test items were administered orally for 15 days. Serum ACE activity was measured on days 1 and 15. Groups B, C and D had significantly lower average serum ACE activity compared to baseline and to the control group, on both days 1 and 15. There were no significant differences in average ACE activity between groups B, C and D. Noninferiority of group C to B was demonstrated. In conclusion, 0.25–0.5 mg/kg benazepril administered BID produced noninferior inhibition of serum ACE activity compared to 0.5–1.0 mg/kg benazepril dosed SID. Pimobendan had no significant effect on benazepril's action on serum ACE activity. The results support the use of benazepril BID in dogs and in combination with pimobendan.